RT Journal Article
SR Electronic
T1 SARS-CoV-2 variant transmission in a community-health population (Mexico City, Mexico)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.18.21264783
DO 10.1101/2021.10.18.21264783
A1 Zhang, Wenjuan
A1 Martinez, Marcela
A1 Davis, Brian D
A1 Chen, Stephanie S
A1 Martinez, Jorge Sincuir
A1 Corona, Clara
A1 Diaz, Guadalupe
A1 Makhoul, Elias
A1 Heneidi, Saleh
A1 Goldberg, Jorge
A1 Plummer, Jasmine T
A1 Vail, Eric
YR 2021
UL http://medrxiv.org/content/early/2021/10/20/2021.10.18.21264783.abstract
AB The SARS-CoV-2 variant, B.1.1.519, arose in North and Central America, circulating primarily in Mexico. We demonstrate that this variant peaked during the second wave of COVID-19 in Mexico City in the spring of 2021. This variant is likely more infectious, attributed to mutation in the RBD of the spike protein T478K also seen in the alpha variant (B.1.1.7). However the time dynamics of the spread of this variant drastically changed upon the introduction of delta (B.1.617.2) to the country in which we observe a shift from 0% in May 2021 to 55% delta in the span of one month. Since the delta variant has dominantly spread across the globe, we investigated the increasing frequency of the Mexico variant, B.1.1.519, in the public community within Mexico City. Once present, the delta variant was 78% of the Mexico City catchment in July 2021, a time which marked the commencement of Mexico’s third wave. Our data supports the growing concern that the delta variant is closely associated with the massive infection spread of the VOC in Central and South America. While the T478K mutation, also seen in the alpha variant, has evidence for increased transmissibility, these data suggest that the delta variant shows overall increased fitness seeing as it outcompeted the B.1.1519 this Mexico community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding provided by Cedars-Sinai InternationalAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Appropriate regulatory review was completed by the CSMC Office of Research Compliance and Quality Improvement (IRB #629_MOD6887)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors